CURRENT ISSUE
April, 2021

No. 106 (4)

2019 Impact Factor: 7.116
ARTICLES IN THREE SENTENCES
Article

CD28.OX40 co-stimulatory combination is associated with long in vivo persistence and high activity of CAR.CD30 T-cells

This pre-clinical study evaluated a chimeric antigen receptor construct characterized by a novel anti-CD30 single-chain variable-fragment cassette, linked to CD3ζ by the signaling domains of CD28.4-1BB or CD28.OX40. The authors concluded that the CD28.OX40 co-stimulatory combination is a very promising therapeutic strategy for patients with CD30+ non-Hodgkin lymphoma or Hodgkin lymphoma.

Marika Guercio et al.

Article

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies

This clinical study retrospectively evaluated the effect of romiplostim in 173 patients with solid tumor, lymphoma or myeloma and chemotherapy-induced thrombocytopenia. Romiplostim was effective in patients with solid tumors: 79% avoided chemotherapy dose reductions/treatment delays, and 89% avoided platelet transfusions. The rate of response to romiplostim in patients with hematologic malignancies was 10%.

Hanny Al-Samkari et al.

Article

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

The authors of this study determined the combined activity of venetoclax and FLT3-ITD inhibition in preclinical models of FLT3-ITD+ acute myeloid leukemia. They observed that FLT3-ITD inhibition combined with venetoclax had impressive anti-tumor activity and suggest that results of this study provide a strong mechanistic rationale for clinical studies.

Raghuveer Singh Mali et al.

Letter

Sex-specific transcriptional profiles identified in β-thalassemia patients

In this study the gene expression profiles of β-thalassemia intermedia and major were analyzed by RNA sequencing. This approach identified sex differences suggesting that males and females are differentially affected by β-thalassemia. This finding highlights the need for considering sex as an important variable of the disease which should be considered when developing differential diagnostic and therapeutic strategies.

Aikaterini Nanou et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA